Stay updated on Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial
Sign up to get notified when there's something new on the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page.

Latest updates to the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page
- Check6 days agoChange DetectedThe site footer revision marker changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check13 days agoChange DetectedThe ClinicalTrials.gov revision label in the footer changed from v3.7.0 to v3.7.1; the page still displays a 403 error rather than the study record.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record content with an error message and the site header indicating an access restriction.SummaryDifference20%

- Check56 days agoChange DetectedRevision label updated from v3.6.5 to v3.6.6 on the page. This represents a minor publication metadata update and does not modify study content or functionality.SummaryDifference0.1%

- Check77 days agoChange DetectedThe page now shows Revision: v3.6.5, replacing v3.6.4. This appears to be a minor version update to the page rather than a change to study information or functionality.SummaryDifference0.0%

- Check91 days agoChange DetectedThe page now shows a new site revision label: Revision: v3.6.4, replacing the previous Revision: v3.6.3. This indicates an internal platform update rather than changes to the study information.SummaryDifference0.0%

Stay in the know with updates to Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page.